Background Loss of skeletal muscle mass and function in humans is associated with
significant morbidity and mortality. The role of myostatin as a key negative regulator of …

Sarcopenia is the progressive loss of skeletal muscle mass and function with advancing
age, leading to reduced mobility and quality of life. We tested the hypothesis that antibody …

Sarcopenia, or skeletal muscle atrophy, is a debilitating comorbidity of many physiological
and pathophysiological processes, including normal aging. There are no approved …

Myostatin is an endogenous inhibitor of muscle conserved across diverse species. In the
absence of myostatin, there is massive muscle growth in mice, cattle, and humans. Previous …

A human therapeutic that specifically modulates skeletal muscle growth would potentially
provide a benefit for a variety of conditions including sarcopenia, cachexia, and muscular …

Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target
for muscle disease therapy because of its role as a negative regulator of muscle growth and …

Increasing the size and strength of muscles represents a promising therapeutic strategy for
musculoskeletal disorders, and interest has focused on myostatin, a negative regulator of …

Myostatin is a secreted protein that negatively regulates skeletal muscle mass determining
both muscle fiber number and size. The myostatin pathway is conserved and regulates …

Myostatin, or GDF-8 (growth and differentiation factor-8), was first identified through
sequence identity with members of the BMP (bone morphogenetic protein)/TGF-β …

Inhibitors of myostatin, a negative regulator of skeletal muscle mass, are being developed to
mitigate aging‐related muscle loss. Knock‐out (KO) mouse studies suggest myostatin also …